ProPhase Labs, Inc. Q2 FY2025 earnings call

• Crown Medical Collections: Planning to sue 1,100 insurance companies for underpayment of COVID-19 test reimbursements. Using Crown Medical collections with contingency fee attorneys, anticipating a court date in 4 - 8 weeks. The potential net cash recovery is ~$50 million.
• BE-Smart Esophageal Cancer Test: Awarded a patent for 8 protein biomarkers. Working towards commercialization, with next steps including publication in major journals, involving key opinion leaders, and reaching out to gastroenterologists (GIs).
• Nebula Genomics: Restructured by Jason Karkus, with shut down lab, revised go-to-market strategy. Working with ThinkEquity on strategic alternatives, potential value increase with capital and advertising.
• Crypto Treasury Strategy: Discussing potential entry into crypto with major players. Need to vote on a proxy to increase authorized shares to 1 billion for future fundraising, with no immediate need to sell shares if not desired.

ProPhase Labs has several segments. The BE-Smart esophageal cancer test segment has a newly awarded patent for 8 protein biomarkers related to esophageal cancer development, with potential for significant revenue but no specific absolute revenue figures or revenue contribution percentage provided. The Nebula Genomics segment has been restructured by Jason Karkus, with shut down lab, revised go-to-market strategy, but no absolute revenue numbers. The ProPhase supplements segment is a historical business, currently less important. The Crown Medical collections segment is targeting over $50 million in net near-term cash recovery from COVID-19 receivables, which is more than 3x the company's current market cap.

• Crown Medical: Anticipate court date in 4 - 8 weeks for suing insurance companies.
• BE-Smart: Anticipate press releases on commercialization progress in the coming weeks.
• Crypto: Upcoming press release on crypto treasury strategy, need to vote on proxy to increase authorized shares for future partnerships and fundraising.

• Insurance Company Resistance: Insurance companies may not settle easily, and there could be delays in court proceedings.
• Clinical Study Delays: Equivir clinical study results are delayed due to a CRO in another country taking time to respond to questions.
• Dilution Fears: Concerns about potential dilution from the crypto strategy, but management assures no need to sell shares if not desired.

Q: Progress for BE-Smart, what are the next steps?

A: The next step is to get a study published in a major journal, then pull in key opinion leaders, and start reaching out to a group of GIs or hospital networks to use the test.

Q: When will the esophageal cancer test hit retail markets?

A: This isn't sold retail. It's added to the endoscopy process, with no additional steps for the patient. Next steps include publication and GI adoption.

Q: Are you able to give us an update on timing of when you expect to start collecting from Crown?

A: Anticipate court date in 4 - 8 weeks, then will start reaching out aggressively to insurance companies.

Q: Can you tell us what line of crypto investing opportunities you're looking at?

A: Focus is on Bitcoin, talking to major players, with more detail to come in a separate press release.

Q: Will investors be diluted because of the crypto? We trust Ted, but we're afraid.

A: We don't have to sell a single share of stock if we don't want to. The idea is to build value, and there are multiple opportunities to increase value without immediate dilution if not selling shares.